You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. NKARTA INC

Nkarta Inc XNAS: NKTX

Nkarta Inc Live Share Price Today, Share Analysis and Chart

Download real time

1.97 0.60 (43.80%)

New 52W Low in past week

27.2M XNAS Volume

High volume+gain today

XNAS 27 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
Board Meeting
The next board meeting for Nkarta Inc is on 28 Mar 2025 for the purpose of Nkarta Inc Annual Report for 2024 See details

Nkarta Inc Key Metrics

Select

Market Capitalization

Below industry Median
139

PE TTM

Negative PE TTM
-1.3

PEG TTM

Negative PEG TTM
-0.1

Price to Book

Low in industry
0.3

Institutional holding current Qtr %

High in industry
93

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-10.5

Net Profit TTM Growth %

Below industry Median
9.6

Piotroski Score

Below industry Median
1

Rel Perf vs Sector quarter%

-19.5

ROE Annual %

Negative ROE Annual %
-36.4

RoA Annual %

Negative RoA Annual %
-27.6
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Not Eligible
-
Valuation Score
Expensive Valuation
15.0 / 100
Momentum Score
Technically Bearish
26.7 / 100
Analyst Price Target
No estimates available

17

S

9

W

2

O

2

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Nkarta Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Nkarta Inc Stock Analysis

Nkarta Inc stock analysis with key metrics, changes, and trends.

Nkarta Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Net Profit$117.5 M3.95%positive

Annual Net Profit rose 3.95% in the last year to $117.5 M. Its sector's average net profit growth for the last fiscal year was -32.45%.

Price to Earning Ratio-1.26-negative

Price to Earning Ratio is -1.26, which is negative.

Stock Price$1.97-80.04%negative

Stock Price fell 80.04% and underperformed its sector by 86.67% in the past year.

Quarterly Net profit$28.34 M10.52%negative

Quarterly Net profit fell 10.52% YoY to $28.34 M. Its sector's average net profit growth YoY for the quarter was -47.41%.

Debt to Equity Ratio0.32-positive

Debt to Equity Ratio of 0.32 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-36.41 %-36.41%negative

Return on Equity(ROE) for the last financial year was -36.41%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding25.59 %1.08%positive

Mutual Fund Holding increased by 1.08% in the last quarter to 25.59.

Institutional Holding92.95 %-2.91%negative

Institutional Holding decreased by 2.91% in the last quarter to 92.95.

VIEW LESS


Loading data..

Nkarta Inc - Company Profile

What does Nkarta Inc do?

Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.

Nkarta Inc Management structure

All Gross Remunerations are in USD
Mr. Paul J. Hastings
Chief Executive Officer and Director
-
2024
Gross Remuneration
Year
Dr. James Trager, PhD
Chief Scientific Officer
-
2024
Gross Remuneration
Year
Dr. David R. Shook, M.D.
Chief Medical Officer and Head of Research and Development
-
2024
Gross Remuneration
Year
Dr. Nadir Mahmood, PhD
President
-
2024
Gross Remuneration
Year

Nkarta Inc Board of directors

All Gross Remunerations are in USD
Mr. Paul J. Hastings
Chief Executive Officer and Director
-
2024
Gross Remuneration
Year
Dr. Fouad Azzam, M.B.A.,PhD
Independent Director
-
2024
Gross Remuneration
Year
Mr. George Vratsanos, M.D.
Independent Director
-
2024
Gross Remuneration
Year

Nkarta Inc FAQ

How is Nkarta Inc today?
Nkarta Inc today is trading in the green, and is up by 43.80% at 1.97.
Nkarta Inc is currently trading up 43.80% on an intraday basis. In the past week the stock rose 29.61%. stock has been down -15.45% in the past quarter and fell -80.04% in the past year. You can view this in the overview section.